Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy

SummaryGlioblastoma (GBM) is the most frequent malignant primary brain tumor in adults and, despite recent advances, the prognosis for this cancer remains dismal. The aims of this study were to test the influence ofXRCC1 rs25487,XRCC3 rs861539, XRCC3 rs1799794,RAD51 rs1801320 andGSTP-1 rs1695 single nucleotide polymorphisms on progression free survival (PFS) and overall survival (OS) in GBM patients treated with radiotherapy (RT) and temozolomide (TMZ). Fifty GBM patients treated with upfront radio-chemotherapy (RT 60  Gy/30 sessions; TMZ 75 mg/m2 during RT and 200  mg/m2 days 1 → 5 every 28 days) were enrolled. Survival curves were calculated using the Kaplan-Meier method, and the log-rank test was used to evaluate differences between curves. A trend to a statistically significant association with PFS in univariate and multivariate COX regression analysis was found withGSTP-1 rs1695 polymorphism (p = 0.087 andp = 0.097 on univariate and multivariate analyses, respectively). Conversely, the sameGSTP-1 rs1695 SNP revealed a statistically significant association with OS (p = 0.007 andp = 0.042 on univariate and multivariate analysis, respectively). Our pharmacogenetic prospective study suggests thatGSTP-1 rs1695 genotypes can be associated with different OS in GBM patients treated with RT and TMZ.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research